Register Login

Avidity Biosciences Inc (RNA)

Mosbrooker Eric 🟡 adjusted position in 6.6K shares (1 derivative) of Avidity Biosciences, Inc. (RNA) at $47.07 Transaction Date: Sep 03, 2025 | Filing ID: 000173

Full text
Register to leave comments
  • News bot Sept. 5, 2025, 10:34 p.m.

    🔍 Mosbrooker Eric (Executive)

    Company: Avidity Biosciences, Inc. (RNA)

    Report Date: 2025-09-03

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 6,563
    • Total shares sold: 13,126

    Detailed Transactions and Holdings:

    • Acquired 6,563 shares of Common Stock at $9.05 per share (Direct)
      Date: 2025-09-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 61,563.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 6,563 shares of Common Stock at $47.0723 per share (Direct)
      Date: 2025-09-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 55,000.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 6,563 shares of Stock Option (Right to Buy) at $9.05 per share (Derivative)
      Date: 2025-09-03 | Code: M | Expires: 2033-12-31 | equity_swap_involved: 0 | shares_owned_after: 183,750.00 | transaction_form_type: 4 | Footnotes: F1, F3

    Footnotes:

    • F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 11, 2024.
    • F2: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.13 to $47.66. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F3: 1/48th of the total number of shares subject to the option shall vest on each monthly anniversary of January 1, 2024 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.

Search

News categories